HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lamaur sells Style

This article was originally published in The Rose Sheet

Executive Summary

Hair care manufacturer signs letter of intent to sell value-priced Style hair care line to New Brunswick, N.J.-based USA Detergents, Lamaur announces. Expected to close by April 30, sale is in line with Lamaur's initiative to rejuvenate its brand portfolio by shifting focus from "classical" brands towards those developed through exclusive licensing agreements. Lamaur sold Willow Lake hair care to Allegheny Pharmacal in November (1"The Rose Sheet" Nov. 19, 2001, p. 9). Company continues to market value brand Salon Style, which could be candidate for divestiture, company says. Two companies also will jointly distribute Lamaur hair care products and USA Detergent personal care and home products to enhance firms' "global business posture," Lamaur says...

You may also be interested in...



Lamaur George Caroll Hair Care To Bring Studio Style To Mass Outlets

Lamaur will expand its mass market hair care portfolio with George Caroll Studio Style, a mid- to premium-priced offering that will debut on a major television shopping network in February before rolling out to mass market retailers in the spring, CEO Lawrence Pesin stated

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel